On Tuesday, Krystal Biotech received an upgrade to its Relative Strength (RS) Rating, from 61 to 73.
IBD's unique RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the market's biggest winners often have an 80 or better RS Rating as they launch their biggest runs. See if Krystal Biotech can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Krystal Biotech is not currently near a potential buy zone. See if the stock goes on to build a promising consolidation that could kick off a new price move.
Earnings growth rose in the company's most recent report from 0% to 407%, but the top line fell from 879% to 116%.
The company holds the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics and Krystal Biotech are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
